GlassScriptPhysician profile
Clara Padron-Spence
NPI 1689693962
$8,092.92
in general payments reported to CMS, 2019-2025
33 companies · $1,970 in 2025
The $1,970 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $120 · 2021: $639 · 2022: $1,216 · 2023: $1,467 · 2024: $2,332 · 2025: $1,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,769.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,007.54 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,421.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $736.73 | 2021-2025 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $688.54 | 2020-2025 | Mounjaro, Jardiance, Kisunla |
| Corcept Therapeutics | $400.25 | 2023-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $366.69 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $316.35 | 2023-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.49 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $273.71 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $238.76 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $197.02 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.19 | 2019-2024 | Trulance |
| Nevro Corp. | $157.17 | 2022-2023 | Senza |
| Neurocrine Biosciences, INC. | $139.90 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.22 | 2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $75.87 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $71.25 | 2021-2023 | Gvoke Hypopen, Keveyis |
| Abbvie INC. | $69.76 | 2019-2021 | |
| Exact Sciences Corporation | $54.63 | 2023-2024 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $49.33 | 2019 | |
| Paratek Pharmaceuticals, INC. | $27.99 | 2025 | Nuzyra |
| Ironwood Pharmaceuticals, INC | $26.54 | 2022 | |
| Biogen, INC. | $25.77 | 2025 | Zurzuvae |
| Daiichi Sankyo INC. | $25.02 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.61 | 2025 | Givlaari |
| Alkermes, INC. | $21.22 | 2023 | Lybalvi |
| Medtronic Vascular, INC. | $19.98 | 2019 | |
| Merck Sharp & Dohme LLC | $19.95 | 2020 | |
| Cequr Corporation | $19.07 | 2025 | Cequr Simplicity |
| Stryker Corporation | $18.86 | 2023 | Claw II, 7 X 23mm Citrelock Implant, Allomatrix |
| Takeda Pharmaceuticals U.S.A., INC. | $18.51 | 2022 | |
| Hologic Sales and Service, LLC | $15.95 | 2025 | Aptima |
| Abbott Laboratories | $13.82 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Padron-Spence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.